吉貝爾(688566.SH):化學原料藥阿替洛爾的上市申請獲批
格隆匯9月14日丨吉貝爾(688566.SH)公佈,近日,公司收到國家藥品監督管理局簽發的《化學原料藥上市申請批准通知書》,化學原料藥名稱為阿替洛爾(Atenolol)。
阿替洛爾主要用於治療高血壓、心絞痛、心肌梗死,也可用於心律失常、甲狀腺機能亢進、嗜鉻細胞瘤。阿替洛爾為選擇性β1腎上腺素受體阻滯劑,不具有膜穩定作用和內源性擬交感活性,但不抑制異丙腎上腺素的支氣管擴張作用。阿替洛爾和阿替洛爾片已被收入《中華人民共和國藥典》,還被列入《國家基本醫療保險、工傷保險和生育保險藥品目錄》中抗高血壓藥物的甲類品種。
近年來,公司積極佈局高血壓防治領域,大力推廣擁有自主知識產權的一類複方抗高血壓新藥——尼羣洛爾片,該產品用於治療輕中度原發性高血壓,更適用於輕中度高血壓合併心率加快患者,在高血壓伴高心率細分疾病領域具有顯著優勢。阿替洛爾原料藥作為尼羣洛爾片的主要成分,是生產尼羣洛爾片所必須的原料之一,為了防止阿替洛爾原料藥市場變化、質量風險等因素對公司產品尼羣洛爾片的生產可能產生的不利影響,公司通過自行開發阿替洛爾原料藥,優化合成工藝、提高質量標準,有效保障尼羣洛爾片的生產需求,降低不確定性風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.